Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

NCT05851443 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05851443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05851443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 11, 2023
Completion date
July 5, 2027
Enrollment
247 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe asthma